Amphastar Pharmaceuticals to Report Fourth Quarter 2025 Earnings

RANCHO CUCAMONGA, CA – February 20, 2026 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) today announced that it will release its fourth quarter 2025 financial results after market close on Thursday, February 26, 2026. A conference call will follow at 2:00 p.m. Pacific Time to discuss the results.

Conference Call Details

Investors can access the conference call by dialing toll-free 877-407-0989. For international calls, the dial-in number is 201-389-0921. Participants should dial in ten minutes before the scheduled start time.

A live webcast of the call will be available on the Investors page of the Company’s website, www.amphastar.com. A replay of the webcast will be available on the website within 24 hours of the call’s conclusion.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. Is a biopharmaceutical company specializing in the development, manufacturing, marketing, and sale of technically complex generic and proprietary injectable, inhalation, and intranasal products. The company also markets insulin API products. Many of Amphastar’s finished products are utilized in hospital and urgent care settings, distributed through group purchasing organizations and drug wholesalers.

Amphastar’s product portfolio includes BAQSIMI, a nasal spray for severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for asthma relief; Enoxaparin for the prevention and treatment of deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kits; and Cortrosyn, a diagnostic agent for adrenocortical insufficiency.

Forward-Looking Statements

This press release contains forward-looking statements, including expectations regarding future financial performance and business trends. These statements are based on Amphastar’s current expectations and are subject to risks and uncertainties. Actual results may differ materially from those expressed in these forward-looking statements. Factors that could cause such differences are detailed in Amphastar’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. Amphastar undertakes no obligation to revise or update these forward-looking statements.

Investor Contact

Bill Peters
Chief Financial Officer
(909) 476-3416